Loading
A phase 3 trial of Sonrotoclax, Zanubrutinib in mantle cell lymphoma, run by BeOne Medicines, now recruiting.
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL) is a phase 3 interventional study registered as NCT06742996 by BeOne Medicines, with 300 participants planned, started 2025-03-05 and due to reach its primary completion in 2028-08-31. Interventions recorded: Sonrotoclax, Zanubrutinib, Placebo. Conditions listed: Mantle Cell Lymphoma, B Cell Lymphoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Sonrotoclax, Zanubrutinib, BCL-2 inhibitors, BeOne Medicines (formerly BeiGene).
Shares Sonrotoclax, BCL-2 inhibitors, BeOne Medicines (formerly BeiGene), Mantle cell lymphoma.
Shares Sonrotoclax, Zanubrutinib, BCL-2 inhibitors, BeOne Medicines (formerly BeiGene).
Shares Sonrotoclax, Zanubrutinib, BCL-2 inhibitors, BeOne Medicines (formerly BeiGene).
Shares Sonrotoclax, Zanubrutinib, BCL-2 inhibitors, BeOne Medicines (formerly BeiGene).
Shares Sonrotoclax, BCL-2 inhibitors, BeOne Medicines (formerly BeiGene), Small-molecule kinase inhibitors.
Shares Sonrotoclax, BCL-2 inhibitors, BeOne Medicines (formerly BeiGene), Small-molecule kinase inhibitors.
Shares Zanubrutinib, BeOne Medicines (formerly BeiGene), Small-molecule kinase inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/